Your browser doesn't support javascript.
loading
Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial.
Reck, Martin; Barlesi, Fabrice; Yang, James Chih-Hsin; Westeel, Virginie; Felip, Enriqueta; Özgüroglu, Mustafa; Dols, Manuel Cobo; Sullivan, Richard; Kowalski, Dariusz M; Andric, Zoran; Lee, Dae Ho; Sezer, Ahmet; Hu, Ping; Wang, XiaoZhe; von Heydebreck, Anja; Jacob, Natalia; Mehr, Keyvan Tadjalli; Park, Keunchil.
Affiliation
  • Reck M; LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany. Electronic address: m.reck@lungenclinic.de.
  • Barlesi F; Université Paris Saclay, Faculté de Médecine, Kremlin Bicêtre, France; Medical Oncology department, Gustave Roussy, Villejuif, France; Present Address: Université Paris Saclay, Faculté de Médecine, Kremlin Bicêtre, France; Medical Oncology Department, Gustave Roussy, Villejuif, France.
  • Yang JC; National Taiwan University Hospital, Taipei, Taiwan.
  • Westeel V; Hôpital Jean Minjoz, Centre hospitalier universitaire de Besançon, UMR1098, Université de Franche, Comté, France.
  • Felip E; Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Özgüroglu M; Department of Internal Medicine, Division of Medical Oncology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey.
  • Dols MC; Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, Málaga, Spain; Present address: UGC Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain.
  • Sullivan R; Auckland City Hospital, Auckland, Australia.
  • Kowalski DM; Department of Lung Cancer and Thoracic Tumours, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Andric Z; Clinical Center Bezanijska Kosa, Belgrade, Serbia.
  • Lee DH; Asan Medical Center, Seoul, South Korea.
  • Sezer A; Baskent University Adana Application and Research Center, Adana, Turkey.
  • Hu P; EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts.
  • Wang X; EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts.
  • von Heydebreck A; the healthcare business of Merck KGaA, Darmstadt, Germany.
  • Jacob N; the healthcare business of Merck KGaA, Darmstadt, Germany.
  • Mehr KT; the healthcare business of Merck KGaA, Darmstadt, Germany.
  • Park K; Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Present Address: MD Anderson Cancer Center, Houston, Texas.
J Thorac Oncol ; 19(2): 297-313, 2024 02.
Article in En | MEDLINE | ID: mdl-37748693
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Antibodies, Monoclonal, Humanized / Lung Neoplasms Type of study: Clinical_trials Limits: Adult / Humans Language: En Journal: J Thorac Oncol Year: 2024 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Antibodies, Monoclonal, Humanized / Lung Neoplasms Type of study: Clinical_trials Limits: Adult / Humans Language: En Journal: J Thorac Oncol Year: 2024 Document type: Article Country of publication: